In patients with familial chylomicronaemia syndrome, volanesorsen reduced mean triglyceride (TG) levels by 77% at 3 months, compared to an 18% increase with placebo (p<0.001).
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
